In this study, the high TBRS scores in desmoid tumors compared to other sarcoma types may reflect their insensitivity to chemotherapy, and further suggest that targeting the TGF-β pathway could be an effective method for treating patients with desmoid tumors. This evidence concerns the gene TGFB1 and desmoid tumor.